Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

GlobeNewswire October 14, 2020

SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference

GlobeNewswire October 12, 2020

SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim's Antifungal Webinar

GlobeNewswire September 10, 2020

SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp's Potential for the Treatment of Vulvovaginal Candidiasis

GlobeNewswire August 13, 2020

SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire August 10, 2020

SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis

GlobeNewswire July 29, 2020

SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

GlobeNewswire July 22, 2020

SCYNEXIS Announces One-for-Ten Reverse Stock Split

GlobeNewswire July 16, 2020

SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections

GlobeNewswire July 9, 2020

To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt's Board of Directors

GlobeNewswire July 6, 2020

SCYNEXIS to Present at the BIO Digital International Convention 2020

GlobeNewswire June 8, 2020

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

GlobeNewswire June 2, 2020

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire May 11, 2020

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

GlobeNewswire May 6, 2020

SCYNEXIS to Participate in Antifungals Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

GlobeNewswire April 28, 2020

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

GlobeNewswire April 21, 2020

SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement

GlobeNewswire April 13, 2020

SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital

GlobeNewswire April 9, 2020

SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

GlobeNewswire March 26, 2020

SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

GlobeNewswire March 11, 2020